INTRODUCTION
The therapeutic as well as the harmful effects of light have been known for a long time. Also, the use of light combined with photosensitizers for therapeutic purposes has been in use for some time. For instance, in skin diseases such as psoriasis and vitiligo, ultraviolet A irradiation in conjunction with oral intake of 8-methoxypsoralen (8-MOP) has been an established therapy (psoralen/ultraviolet A treatment, or PUVA) for many years [ 1, 2, 3] .
As a further development in this field, a new extracorporeal photochemotherapy technique (UVAR' System) was first reported by Edelson et al. [4, 5] for the treatment of cutaneous T-cell lymphoma (CTCL) patients. As discussed by other authors in this issue, this technique has a potential application in many other diseases. In order to develop an optimized treatment procedure for different patients and diseases, it is essential to know the physical parameters and engineering aspects of this new technique.
In extracorporeal photochemotherapy, three major elements-target cells, photosensitizer, and light-are involved. Ideally, the goal of this therapy is to deliver a predetermined amount of light energy at a specific wavelength, or a range of wavelengths, to the selected target blood cells only when these cells contain a predetermined amount of photoactivatable drug. Since there are significant differences between photodynamic therapy and broad-band photochemotherapy, this discussion will be limited to the broad-band extracorporeal photochemotherapy (photopheresis).
SYSTEM MODELS OF PHOTOPHERESIS This new extracorporeal photochemotherapy can be achieved by following three different methods. Obviously, many modified versions of each of these methods can be designed to optimize the overall treatment system under given conditions. The methods In this method, a fraction of the patient's circulating blood is removed from the patient, exposed to the therapeutic light for a predetermined period, and returned to the patient. Only one batch of blood, whether collected by one collection cycle or multiple collection cycles, is exposed to the light. For example, in the UVAR photopheresis system, normally the buffy coat is collected by six cuts. The irradiated blood fraction could be whole blood or a fractionated blood component, such as buffy coat or a specific cell fraction.
When the light source is ultraviolet (UV) light and the target cell is other than red blood cells (white blood cells or platelets for example), it will be much more effective to remove the red blood cells from the irradiation circuit to the greatest extent possible and to minimize the shielding effect of red blood cells. The fraction of treated target cells to total target cells in the patient's circulating system can be expressed by:
F=- [1 ] NT where NP is the number of treated cells and NT is the total number of target cells in the patient's circulating blood. The patient's circulating whole blood volume can be estimated by using 78 ml per kilogram of body weight [6] . A more accurate estimation can be made based on sex, body weight, and height [7] .
In UVARe photopheresis, the white blood cell yield in buffy coat is a function of white blood cell count and hematocrit of patient whole blood. With normal blood cell counts, the yield is approximately 50 percent of processed whole blood. Normally, 1.5 liters of the patient's whole blood are processed in the UVAR photopheresis system. Therefore, for example, in the case of a 65 kg patient with normal blood counts, approximately 15 percent of the patient's white blood cells in the circulation will be treated by the UVAR photopheresis process.
Multiple-Batch System
When the multiple-batch system is used, a portion of the patient's circulating blood is removed from the patient, exposed to the light, and returned to the patient. In this system, the process is repeated multiple times. The number of repetitions is a complex function of many parameters such as total number of target cells to be treated, blood cell counts, batch volume, patient's peripheral blood volume, and UVA irradiance. Since already treated blood cells are returned to the patient before the next batch of blood is removed, some target cells will be treated repeatedly by this method. Assuming that the blood in the patient's body is well mixed and also that the diffusion and exchange rates of target cells between the circulating blood system and other organs are negligible during this treatment period, the fractions of treated and F= I -(I _f)n [2] Normally, the patient cannot tolerate removal of more than 10 percent of the circulating blood volume, and usually the total extracorporeal blood volume in a therapeutic device is much less than that. Therefore, the values of the terms withf2 or a higher power in the above equation are very small.
Continuous Single-Pass Method
In the continuous single-pass method, a portion of the patient's peripheral blood is continuously circulated through an extracorporeal circuit in which the blood or the desired fraction of it is exposed to the light for a predetermined period (residence time) and returned to the patient, a continuous, on-line, single-pass procedure. The fraction of the target cells treated at least once can be expressed by the following equation:
where VPB is the patient's circulating peripheral blood volume, QB iS the extracorporeal blood flow rate, t is the total irradiation period (treatment time), and C is the efficiency factor. The value of C is 1.0 if all target cells passing through the irradiation chamber receive the same amount of light energy, target value. As in the case of the multiple-batch method, there will be a distribution of target cells which receives multiple treatments. Therefore, when the therapy is to deliver a specific amount of light energy to individual cells and to avoid multiple exposure, the single-batch method would be the most desirable. If, however, only a small fraction of total target cells are treated, the number of cells receiving multiple treatments will be very small and insignificant.
CELL SEPARATION Due to the absorptivity of red blood cells, especially to UV light, it is desirable to reduce the red blood cell concentration of the blood in the irradiation circuit to minimize the red blood cell shielding effect. For instance, in the UVAR photopheresis system, the target cells are white blood cells, especially lymphocytes, and the light source is a broad-band UVA light (320 -400 nm). The process consists of three major steps: (I) the patient's blood is drawn two hours after oral intake of the photoactivatable drug (8-MOP), and buffy coat is collected by centrifugal technique; (2) the collected buffy coat is diluted in saline and the patient's plasma, irradiated by ultraviolet A light (UVA light) in an irradiation chamber for a predetermined period; and, finally, (3) the irradiated buffy coat is returned to the patient. One of the key steps in this system is to reduce the red blood cell contamination in the collected buffy coat as If whole blood in a test tube is allowed to stand overnight and earth's gravity is permitted to act on individual blood components, the blood will separate into three distinctive layers: a packed red blood cell layer at the bottom, a thin buffy coat layer in the middle, and an amber plasma layer on the top. The sedimentation rate of blood cells in a given gravitational field varies, depending on density, size, shape, and other physical properties of blood cells. Table 1 shows the average physical characteristics of normal adult human blood cells.
Red blood cells not only have higher density but also tend to adhere to each other and form much larger particles, or rouleaux, in a low shear rate region (<50 sec') such as stagnant or slowly moving blood.
In a gravitational field such as that inside a centrifuge bowl, the red blood cells, in rouleaux form, settle to the bottom of the device. Behind the settling red blood cells, the white blood cells and platelets settle on top of the red blood cell layer and form the buffy coat. This sequence is due to the slower sedimentation rates of white blood cells and platelets because of their lower densities and smaller sizes in comparison to the red blood cell rouleaux. Centrifugation speeds up this separation process by means of increased gravitational force. The settling red blood cells (rouleaux) replace plasma and other cells; however, increased cell concentration near the bottom of the device results in increased cell-cell interaction, which causes trapping of many white cells inside the packed red blood cell layer. Also, too high a centrifugal force will result in very rapid settling of all cellular elements, and the small difference in sedimentation rates between red and white blood cells becomes insignificant. When this effect happens, even though the process time is shortened, a poor cell separation will occur. Therefore, the optimal cell separation process requires a delicate adjustment of process variables, including total process time. This optimum condition will vary, depending on the type of cell to be collected and the composition of whole blood, especially hematocrit [8] .
It is known that the lymphocyte cells within the buffy coat layer are more concentrated in the plasma side, while neutrophils and monocytes are higher in concentration near the red blood cell layer or inside it [9] . In UVAR8 photopheresis, the buffy coat collection process was designed so that lymphocyte collection could be maximized while minimizing red blood cell contamination.
UV IRRADIATION UV Energy Delivered
In extracorporeal photochemotherapy, the whole blood or the portion which contains target blood cells and photoactivatable drug is circulated through an irradiation chamber. In the UVARs photopheresis system, the buffy coat solution diluted by plasma and saline is recirculated through a thin fluid path in the PHOTOCEPTOR' irradiation chamber, a molded UVA-transparent acrylic device.
Normally, in photobiological science the light energy delivered to the sample is measured by the amount of energy delivered per unit surface area, J/cm2, because the same surface area is exposed to the light for a specified period. In a case such as UVARD photopheresis, however, the fluid is not transparent to the UV light due mostly to red blood cell shielding, and only the surface of the fluid film is exposed to the irradiation. Since the fluid surface is continuously renewed during the flow, individual target cells in the fluid are exposed to the irradiation for only a fraction of the total exposure period. The light intensity (irradiance) at the surface of the target cell membrane will be a function of the hematocrit, the plasma absorptivity, and the distance the light beam has to penetrate. In the PHOTOCEPTOR® irradiation chamber, the buffy coat film is about 1.4 mm thick, and hematocrit is about 4 to 6 percent on the average. Under these conditions, the blood film is totally opaque to the UVA light, mostly because of the red blood cell shielding. The amount of UVA energy, E, delivered to the circulating buffy coat solution can be best expressed by the amount delivered to the unit volume rather than to the unit surface area: E Io. A .t VB where E = Total UVA energy delivered to the unit volume, J/ml Io = The average intensity of UV light (irradiance) at the blood film surface, w/cm2 A = Total surface area of the blood film exposed to the light, in cm2 t = Total irradiation period, in seconds VB = Total volume recirculated through the irradiation system, in ml For a single-pass irradiation system, the UVA energy delivered can be calculated using the following equation : Io A E= QB where QB = Blood flow rate through the irradiation chamber, in ml/second. The fluid channel in the irradiation chamber has to be designed in such a way that any cell settlement or fluid stagnation should be avoided. In the recirculation system, the light energy delivered to the target cells is independent of the recirculation flow rate, while in the single-pass system it is inversely proportional to the flow rate.
Red Blood Cell Shielding
In extracorporeal photochemotherapy, the shielding effect by red blood cells is one of the major problems. As a sample experiment, human blood buffy coat solutions containing 75 ng/ml of 8-MOP and several different concentrations of red blood cells were exposed to UVA light. The amount of UVA energy required to reduce the white blood cell (mostly lymphocyte) viability after four days to below 20 percent was measured. Figure 1 shows the UVA energy required versus the hematocrit. At zero hematocrit, only 6 J/ml of UVA energy were needed to achieve the goal. As the hematocrit increases, however, the required amount of energy increases almost exponentially. UVA energy is also absorbed by plasma and other blood constituents, but its magnitude is negligible in comparison to the red blood cell effect. Figure 1 implies that the UVA energy absorption by the red blood cell solution closely follows Beer's law. The UVA intensity reaching an individual white blood cell's surface decreases as an exponential function of red blood cell concentration, hematocrit. For instance, at a hematocrit of 8 percent or more, an extremely small fraction of total UVA energy delivered will reach white blood cells; the time required is too long to achieve a desirable photochemical reaction, and the process becomes impractical. Therefore, it is essential to minimize the red blood cell shielding effect by reducing red blood cell concentration. If, however, it takes too long to reduce the red blood cell concentration to the minimum level, it would not be much help in reducing the overall patient treatment period. Therefore, it is necessary to optimize the overall system by balancing the cell separation and irradiation periods.
Light Source and Measurement
The best choice of a light source for photochemotherapy is obviously the one with a maximum output at the wavelength at which the desirable photochemical activity is maximum. Therefore, it is extremely helpful to generate an action spectrum for a given photosensitizer as a function of wavelength and evaluate the shape of the curve. For instance, photosensitized 8-MOP showed the maximum activity in inhibiting new DNA synthesis in human lymphocytes at 346 nm, and its action spectrum is fairly broad [ 10] . In this situation, the most efficient light source is a broad-band fluorescent light source with a maximum output at around 346 nm. The fluorescent light bulb in the UVARs system has its maximum peak at around 350 nm, close to the optimum wavelength of 346 nm. If the action spectrum shows an extremely sharp peak at a certain wavelength, an arc lamp with maximum output at that wavelength, or a laser beam, would be a better choice.
The light intensities from most light sources, including fluorescent bulbs and arc lamps, decay over time. So, in photochemotherapeutic instruments it is necessary to set a limit on the life of the light bulb. Otherwise, the intensity must be monitored before every treatment and the treatment process adjusted accordingly. In the case of ultraviolet light (UV) irradiance measurement, an accurate monitoring requires extremely careful planning. It is not unusual to have completely different UVA irradiance readings by two calibrated UVA detectors from two different manufacturers. For instance, a given UVA detector has its specific response curve as a function of wavelength. Ideally, it should be a constant value, independent of wavelength, within the UVA range (320 -400 nm) and zero at other wavelengths. There is, however, no such ideal detector, and all detectors have their own characteristic response curves. Therefore, the best choice of UVA detector is the one which has a broad response curve with a maximum response at the wavelength at which the light source produces the maximum UVA output.
Also, in order to avoid inaccurate readings caused by solarization and instrument drift, periodic calibration of the monitor is necessary. Considering all these potentially inaccurate measurements of light energy and, therefore, inadequate patient treatment, it would be much safer in many instances to put a limit on the light bulb life. Drug Delivery
As far as the delivery of photoactivatable drug to the target cells is concerned, an on-line drug addition to the extracorporeal blood circuit would be the most efficient approach. In the currently available UVAR® photopheresis system, the drug (8-MOP) is delivered to the target blood cells through oral intake. This route is very inefficient, and it is extremely difficult to adjust the drug concentration in the target cells accurately due to individual variation in bioavailability. On-line drug delivery would not only be precise, but it would also leave a much smaller amount of residual drug in the patient's body after the treatment.
In conclusion, the development of an optimized process for extracorporeal photochemotherapy requires understanding of each engineering element discussed here and adjustment of these elements for overall optimum therapy.
